Center for Traditional Chinese Medicine and Systems Biology, Institute for Interdisciplinary Medicine Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Nutrients. 2017 Oct 16;9(10):1124. doi: 10.3390/nu9101124.
The gut microbiota plays critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes(T2D), and insulin resistance(IR), highlighting the potential of gut microbiota-targeted therapies in these diseases. There are various ways that gut microbiota can be manipulated, including through use of probiotics, prebiotics, synbiotics, antibiotics, and some active components from herbal medicines. In this review, we review the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies for NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiota-targeted therapies in the future.
肠道微生物群在肥胖相关代谢性疾病（如非酒精性脂肪性肝病（NAFLD）、2 型糖尿病（T2D）和胰岛素抵抗（IR））的发展中起着关键作用，这凸显了靶向肠道微生物群治疗这些疾病的潜力。有多种方法可以操纵肠道微生物群，包括使用益生菌、益生元、合生菌、抗生素和一些草药中的活性成分。在这篇综述中，我们回顾了肠道微生物群在介导 NAFLD 发展中的主要作用，以及在实验和临床研究中针对 NAFLD 的靶向肠道微生物群治疗的进展，以及对未来靶向肠道微生物群治疗的展望。
